Q&A – Product launch

2cureX is happy to receive a number of questions and comments from our present and from potential future shareholders.

With the present Questions & Answers (Q&A) section, we would like to make these questions and their answers publicly available. Additional questions/comments should be mailed to info@2cureX.com.

What preparations have been done to prepare for the launch of IndiTreat®?

Posted on 2019-12-05
To prepare for launch, 2cureX has continuously interacted with the target customer segments and mapped their workflow, needs and purchasing pattern. The focus has been on Germany, UK and the Nordics as well as some markets that could be included in the next phase of the launch. 2cureX has also engaged advisors and experts in the field of market access to help optimize the launch strategy.

Is 2cureX discussing the implementation of the test with hospitals in launch countries?

Posted on 2019-11-20
Yes, 2cureX is in direct contact with key opinion leaders (KOL) at university hospitals, large regional clinics, specialized oncology clinics and diagnostic commercial labs. With several of these clinics 2cureX is in an advanced dialogue regarding the implementation of IndiTreat. The customer interactions and dialogue with commercial labs have provided valuable market insights that will benefit the launch.

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

February 25, 2021

Year-End Report 2020

View previous reports

March 2, 2021

Nordnet Online Event

Read more

March 4, 2021

RedEye Investor Forum Online

Read more

March 16, 2021

CEO meets young investors, link to event will follow

Read more

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs